Thermo Fisher Scientific TRAIL-R2 (DR5) Monoclonal Antibody (DR-5-01-1), FITC

Applications

Tested Dilution

Publications

Flow Cytometry (Flow)

1-5 µg/mL

View 2 publications 2 publications

Product Specifications

Species Reactivity

Human

Published species

Human

Host/Isotype

Mouse / IgG1

Class

Monoclonal

Type

Antibody

Clone

DR-5-01-1

Immunogen

Recombinant fusion protein of human IgG heavy chain and extracellular domain of DR5

Conjugate

FITC FITC FITC

Excitation/Emission Max

498/517 nm View spectra

Form

Liquid

Concentration

0.1 mg/mL

Purification

Size-exclusion chromatography

Storage buffer

PBS, pH 7.4, with 0.2% BSA

Contains

15mM sodium azide

Storage conditions

4° C, store in dark, DO NOT FREEZE!

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2534530

Product Specific Information

This antibody recognizes an extracellular domain of TRAIL-R2 (DR5). TRAIL-R2 is one of two TNF superfamily members that contain death domain for TRAIL (APO2L).

Target Information

DR5 (Apo2, TRAIL-R2, TRICK2, KILLER) is a recently identified death domain containing receptor for TRAIL, which mediates TRAIL induced apoptosis. DR5 is a member of the TNF-receptor superfamily, and contains an intracellular death domain. DR5 can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by DR5. Two transcript variants encoding different isoforms of DR5 and one non-coding transcript have been found. Overexpression of DR5 induces apoptosis and activates NF-kappa-B. DR5 is expressed in a number of cell types, and to particularly high levels in lymphocytes and spleen. Diseases associated with DR5 dysfunction include squamous cell carcinoma, and diffuse infiltrative lymphocytosis syndrome.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.